Mathes Company Inc. reduced its position in shares of Merck & Co., Inc. (NYSE:MRK) by 9.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,772 shares of the company’s stock after selling 1,900 shares during the period. Mathes Company Inc.’s holdings in Merck & Co., Inc. were worth $1,056,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. Krilogy Financial LLC raised its holdings in shares of Merck & Co., Inc. by 0.4% in the 2nd quarter. Krilogy Financial LLC now owns 3,129 shares of the company’s stock worth $201,000 after acquiring an additional 11 shares during the last quarter. Balentine LLC grew its position in Merck & Co., Inc. by 1.0% in the 2nd quarter. Balentine LLC now owns 2,107 shares of the company’s stock worth $135,000 after purchasing an additional 20 shares in the last quarter. Jackson Grant Investment Advisers Inc. grew its position in shares of Merck & Co., Inc. by 0.4% during the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 9,291 shares of the company’s stock valued at $595,000 after acquiring an additional 39 shares during the period. Thompson Davis & CO. Inc. grew its position in shares of Merck & Co., Inc. by 0.9% during the 2nd quarter. Thompson Davis & CO. Inc. now owns 4,313 shares of the company’s stock valued at $276,000 after acquiring an additional 40 shares during the period. Finally, Cornerstone Advisory LLP grew its position in shares of Merck & Co., Inc. by 0.4% during the 2nd quarter. Cornerstone Advisory LLP now owns 11,110 shares of the company’s stock valued at $712,000 after acquiring an additional 43 shares during the period. Institutional investors and hedge funds own 74.79% of the company’s stock.
In other news, EVP Michael J. Holston sold 12,500 shares of Merck & Co., Inc. stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $61.63, for a total transaction of $770,375.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Wendell P. Weeks sold 5,000 shares of Merck & Co., Inc. stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $53.57, for a total transaction of $267,850.00. Following the transaction, the director now directly owns 5,100 shares of the company’s stock, valued at $273,207. The disclosure for this sale can be found here. Insiders sold a total of 82,500 shares of company stock valued at $5,026,025 over the last ninety days. 0.25% of the stock is currently owned by insiders.
Merck & Co., Inc. (NYSE MRK) opened at $55.37 on Wednesday. The company has a quick ratio of 1.06, a current ratio of 1.33 and a debt-to-equity ratio of 0.62. The company has a market cap of $149,261.08, a PE ratio of 13.91, a PEG ratio of 2.28 and a beta of 0.81. Merck & Co., Inc. has a 1-year low of $53.12 and a 1-year high of $66.41.
Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Friday, February 2nd. The company reported $0.98 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.94 by $0.04. Merck & Co., Inc. had a net margin of 6.40% and a return on equity of 28.61%. The company had revenue of $10.43 billion for the quarter, compared to analysts’ expectations of $10.48 billion. During the same period in the prior year, the business earned $0.89 EPS. The firm’s quarterly revenue was up 3.1% on a year-over-year basis. research analysts predict that Merck & Co., Inc. will post 4.16 EPS for the current year.
Merck & Co., Inc. announced that its board has initiated a share repurchase plan on Tuesday, November 28th that authorizes the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization authorizes the company to buy shares of its stock through open market purchases. Shares repurchase plans are generally a sign that the company’s board believes its shares are undervalued.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 6th. Investors of record on Thursday, March 15th will be given a $0.48 dividend. This represents a $1.92 annualized dividend and a dividend yield of 3.47%. The ex-dividend date of this dividend is Wednesday, March 14th. Merck & Co., Inc.’s payout ratio is currently 206.45%.
ILLEGAL ACTIVITY NOTICE: This piece was first published by Week Herald and is the property of of Week Herald. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this piece can be read at https://weekherald.com/2018/03/14/mathes-company-inc-has-1-06-million-position-in-merck-co-inc-mrk.html.
Merck & Co., Inc. Profile
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.